High-Risk IV Medications in Special Patient Populations 1st Editon 2014 Softbound at Meripustak

High-Risk IV Medications in Special Patient Populations 1st Editon 2014 Softbound

Books from same Author: Sandra Kane-Gill, Joseph Dasta

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Retail Price: ₹ 13529/- [ 5.00% off ]

    Seller Price: ₹ 12853

Sold By: Book Upload      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 5.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 5.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Sandra Kane-Gill, Joseph Dasta
    PublisherSpringer
    Edition1st Edition
    ISBN9781447158684
    Pages160
    BindingSoftbound
    LanguageEnglish
    Publish YearAugust 2014

    Description

    Springer High-Risk IV Medications in Special Patient Populations 1st Editon 2014 Softbound by Sandra Kane-Gill, Joseph Dasta

    Critical Care Clinicians can use general drug references (Micomedex, Lexicomp) for data on dosing of high-alert medications in special patient populations but these references are not available to all healthcare clinicians, they are expensive and they are not specific to high-alert medications or critically ill patients. Doctors, nurses and pharmacists in the hospital setting will benefit from having one resource with all of this information. The purpose of this reference manual would be to guide critical care clinicians on dosing of high-alert medications in special patient populations. The most important feature of the book will be a summary of primary literature using tables when possible. This will be useful to readers because currently a reference book does not exist that guides clinicians in these difficult dosing decisions. Anesthetic agents (general, inhaled, intravenous).- Propofol, ketamine, etc.- Anti-infectives.- aminoglycosides, vancomycin, drotrecogin, amphotericin products.- inhaled agents.- Anticoagulants agents.- unfractionated heparin, low molecular weight heparins, fondaparinux, lepirudin, argatroban, bivalrudin, abciximab, eptifibatide, tirofiban.- Thrombolytics –reteplase, tenecteplase, streptokinase, urokinase, alteplase.- Cardiac Drugs.- Adrenergic agents.- dopamine, dobutamine, vasopressin, , nitroglycerin, nitroprusside epinephrine, norepinepherine, phenylepherine.- Adrenergic antagonists.- Propranolol, diltiazem, verapamil, esmolol, labetalol, clevidipine.- Antidyrrhthmics.- amiodarone, lidocaine, procainamide.- Inotropic agents.- milrinone, amrinone, isoproterenol, niseritide, digoxin.- Prostanoids.- Epoprostenol, iloprost, treprostenil.- Electrolytes.- Potassium, magnesium, sodium chloride (hypertonic), cardioplegic solutions.- Hypoglycemics.- Insulin and oral agents.- Neuromuscular blocking agents .- vecuronium, rocuronium, cisatracurium, atracurium, succinylcholine.- Opioids (IV, oral).- Remifentanyl, fentanyl , morphine, hydromorphone, meperidine.- Sedatives (IV, oral and transdermal).- lorazepam, midazolam, diazepam, propofol, dexmedetomidine.- Information for Each Drug.- Propofol .- Normal.- Obese.- Renal Dysfunction.- CrCL.- Dialysis (HD, CRRT).- Liver Dysfunction.- Recommendations for Safe Use.